biostudies-literatureUnknown9Du H<b>Aims:</b> This study aimed to identify potential, non-invasive biomarkers for diagnosis and monitoring of the progress in multiple myeloma (MM) patients. <b>Methods:</b> MM patients and age-matched healthy controls (HC) were recruited in Discovery phase and Validation phase, respectively. MM patients were segregated into active group (AG) and responding group (RG). Serum samples were collected were conducted to non-targeted metabolomics analyses. Metabolites which were significantly changed (SCMs) among groups were identified in Discovery phase and was validated in Validation phase. The signaling pathways of these SCMs were enriched. The ability of SCMs to discriminate among groups in Validation phase was analyzed through receiver operating characteristic curve. The correlations betweenFrontiers in pharmacology884https://www.ebi.ac.uk/biostudies/studies/S-EPMC6113671biostudies-literatureAnalysis of the Metabolic Characteristics of Serum Samples in Patients With Multiple Myeloma.PMC6113671Zhang THuang ZDu HLiu BWang JSu HWang LfalseAnalysis of the Metabolic Characteristics of Serum Samples in Patients With Multiple Myeloma.<b>Aims:</b> This study aimed to identify potential, non-invasive biomarkers for diagnosis and monitoring of the progress in multiple myeloma (MM) patients. <b>Methods:</b> MM patients and age-matched healthy controls (HC) were recruited in Discovery phase and Validation phase, respectively. MM patients were segregated into active group (AG) and responding group (RG). Serum samples were collected were conducted to non-targeted metabolomics analyses. Metabolites which were significantly changed (SCMs) among groups were identified in Discovery phase and was validated in Validation phase. The signaling pathways of these SCMs were enriched. The ability of SCMs to discriminate among groups in Validation phase was analyzed through receiver operating characteristic curve. The correlations between2018-01-01T00:00:00Z20182025-06-01T03:24:36.081Z2025-06-01T03:24:36.081ZS-EPMC61136713018616110.3389/fphar.2018.00884